100 Days Mission to respond to future pandemic threats: Reducing the impact of future pandemics by making Diagnostics, Therapeutics and Vaccines available within 100 days
100 DAYS MISSION to respond to future pandemic threats Reducing the impact of future pandemics by making Diagnostics, Therapeutics and Vaccines available within 100 days A report to the G7 by the pandemic preparedness partnership
This independent report prepared for the G7 by the pandemic preparedness partnership outlines a roadmap to reduce the impact of future pandemics by ensuring diagnostics, therapeutics, and vaccines are available within 100 days. It offers recommendations across research and development, clinical trials, manufacturing, financing, and rules of the road for international coordination. The strategy emphasizes proactive R&D against priority viral families and strengthening global health architecture.
Summary and content fields are drawn from the document text and are pending editorial review.
Who issued it
Who it governs
Governments, international organizations, industry leaders, and researchers should read this to understand how to collaboratively prepare for and respond to future pandemics.
What the document contains
The document addresses strategies, recommendations, and frameworks for developing and deploying safe and effective diagnostics, therapeutics, and vaccines within 100 days of a pandemic threat. It covers R&D prioritization, clinical trial networks, regulatory harmonization, manufacturing capacity, and sustainable international financing.
It does not provide specific technical standards for artificial intelligence, nor does it detail non-medical public health interventions or comprehensive domestic healthcare system strengthening outside the scope of medical countermeasures.
- Safe and effective diagnostics, therapeutics, and vaccines should be deployable within the first 100 days of identifying a pandemic threat.
- Proactive R&D investments in prototype countermeasures and modern platform technologies are essential to prepare for known viral families and unknown threats.
- Embedding best practices during non-pandemic times through networked clinical trials, streamlined regulation, and transferable manufacturing processes is critical.
- A global financing facility triggered automatically upon a Public Health Emergency of International Concern ensures equitable access and at-risk manufacturing.
- Pre-negotiated rules of the road covering data sharing, supply chains, and biological samples prevent wasted time during health crises.
· Foreword · Chapter 1: The Case for a 100 Days Mission · Chapter 2: The Pandemic Preparedness Partnership · Chapter 3: Research & Development to Fill the Gaps in our Arsenal · Chapter 4: Embedding Best Practice Between Pandemics · Chapter 5: Rules of the Road · Annex A: Summary of Recommendations · Annex B: Members of the Pandemic Preparedness Partnership · Glossary of Terms
How it scores
Each score is backed by a quote verified against the document text. Editorial review has not yet confirmed them.
Accountability
3/5Clear responsibility for AI outcomes
We recommend establishing a Global Health Board reporting to the G20 to provide oversight of pandemic readiness on an annual basis.
Chapter 4
screening score · 2026-10-23
Fairness
4/5Non-discrimination and equitable treatment
As part of countries’ bilateral DTV procurement, any advance purchase agreements with manufacturers should include a requirement for products provided to LMICs to be provided at not for profit.
Chapter 5
screening score · 2026-10-23
Human Dignity
0/5Respect for the inherent worth of persons
screening score · 2026-10-23
Human Oversight
0/5Humans remain in control of consequential decisions
screening score · 2026-10-23
Privacy
2/5Protection of personal data and private life
We support their focus on principle-based, privacy-preserving approaches to secure safe sharing and equitable use of data.
Chapter 4
screening score · 2026-10-23
Transparency
3/5Openness about how AI systems work and are used
This includes ensuring that key documents such as protocols, analysis plans, operating procedures and progress reports are in the public domain
Chapter 4
screening score · 2026-10-23
Enforcement
1/5Consequences and compliance mechanisms with real force
G7 CSAs (or equivalents) should provide an update at the proposed stocktake before the end of 2021.
Annex A
screening score · 2026-10-23
Impact Assessment
4/5Required assessment of an AI system's risks/impacts before or during use
We recommend that governments should build in conditions into their DTV funding arrangements to ensure LMIC access to DTVs at not for profit and scale, which is to be enacted if a PHEIC is declared.
Chapter 4
screening score · 2026-10-23